CoA Therapeutics

Executive Summary

CoA Therapeutics is a preclinical-stage biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company is pioneering small-molecule therapies that modulate the coenzyme A (CoA) biosynthetic pathway to address rare genetic disorders with high unmet medical need. Its lead programs target pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs) including propionic acidemia (PA) and methylmalonic acidemia (MMA). By leveraging deep insights into CoA metabolism, CoA Therapeutics aims to restore cellular energy balance and mitigate disease progression. The company is currently advancing its lead candidate through Phase 1 clinical trials, with initial safety and pharmacokinetic data expected in the near term. As a private, early-stage firm, CoA Therapeutics represents a high-risk, high-reward opportunity in the rare disease space, with potential for significant clinical impact if its novel mechanism is validated.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 PKAN Trial Interim Safety Data60% success
• Q4 2026FDA Orphan Drug Designation for Methylmalonic Acidemia80% success
• Q2 2027Initiation of Phase 1/2 Trial for Propionic Acidemia70% success